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Abstract: Type II DNA topoisomerases have the ability to generate a transient DNA 
double-strand break through which a second duplex can be passed; an activity essential for 
DNA decatenation and unknotting. Topoisomerase poisons stabilize the normally transient 
topoisomerase-induced DSBs and are potent and widely used anticancer drugs. However, their 
use is associated with therapy-related secondary leukemia, often bearing 11q23 translocations 
involving the MLL gene. We will explain recent discoveries in the fields of topoisomerase 
biology and transcription that have consequences for our understanding of the etiology of 
leukemia, especially therapy-related secondary leukemia and describe how these findings may 
help minimize the occurrence of these neoplasias.  
Keywords: topoisomerase II; TOP2; translocation; leukemia; AML; etoposide; mitoxantrone; 
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1. Introduction 
Drugs targeting TOP2 (TOP2 poisons) are important and effective anti-cancer agents, but they are 
associated with serious side effects including the development of therapy related acute leukemia (t-AL), 
especially acute myeloid leukemia (t-AML). The incidences of therapy related leukemia are increasing 
due to better survival rates and the use of more intensive chemotherapy regimens to treat primary cancers 
and t-AML generally has a poorer prognosis than de novo AML [1,2]. t-AML accounts for ~15% of all 
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acute myeloid leukemia cases [1] and occurs after treatment for hematological and non-hematological 
malignancies. AML is the most common secondary cancer to occur following treatment of childhood 
acute lymphoblastic leukemia (ALL) for example, where it appears with short latency in a proportion of 
cases who achieve a first complete remission [3]. t-AML also remains a late complication following 
treatment of solid tumors including in breast cancer patients treated with epirubicin or mitoxantrone, 
especially those of a younger age at the time of diagnosis [4–6]. Thus t-AML is an important clinical 
problem. Understanding the mechanisms that cause t-AML may suggest ways to reduce its occurrence.  
Two classes of anti-cancer agents are associated with t-AML; these are alkylating agents and TOP2 
poisons. Both types of agent are cytotoxins widely used in cancer therapy, and achieve their anti-cancer 
activity by generating DNA damage leading to cell death. Alkylating agents chemically react with DNA 
to form inter-strand crosslinks and other DNA adducts. In contrast, as described in more detail below and 
shown in Figure 1, TOP2 poisons interfere with the religation step in the topoisomerase II reaction cycle, 
leading to the accumulation of DNA double-strand breaks (DSBs). The occurrence of t-AML 
presumably reflects non-lethal genetic damage induced by these agents in hematopoietic precursor cells, 
but t-AML cases associated with alkylating agents are biologically and clinically distinct from those 
associated with TOP2 poisons (see Table 1), suggesting different mechanisms of pathogenesis.  
Figure 1. TOP2 mechanism. TOP2 cleaves both strands of a duplex DNA segment (brown,  
1–2). A second DNA duplex (blue) passes through the transient enzyme-coupled break (2–3). 
The first duplex is then re-ligated and the products of the reaction are released from the 
enzyme (4). 
 
Monosomy for chromosome 5 or 7 or loss of 5q or 7q chromosome arms are characteristic of 
alkylating agent-associated t-AML/t-MDS, while karyotypic abnormalities in TOP2 poison associated 
t-AML are typically balanced chromosome translocations [7] that generate novel fusion genes. 
Translocations involving the mixed lineage leukemia locus (MLL) at 11q23 are the most frequent type 
of balanced translocation in t-AML [8,9] and acute leukemias with this translocation appear with a 
short latency period following chemotherapy with TOP2 poisons [7,10]. Other recurrent t-AML 
translocations include t(15,17)(PML-RARA), t(8,21)(AML-ETO) and inv(16)(MYH11-CBFB) [6]. 
Chromosome translocations represent a crucial early event in the development of these leukemias and 
the resulting fusion genes, for example MLL-AF9, are able to transform hematopoietic precursors and 
induce leukemia in animal models [11]. Cytotoxic drugs such as TOP2 poisons are often administered 
in complex regimens with other drugs, and this can make it difficult to assess the leukemogenic effect 
of individual agents. A notable exception to this is the use of mitoxantrone monotherapy to treat 
multiple sclerosis, where secondary leukemia with PML-RARA translocations has been reported as a 
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complication [12–17]. How the chromosome translocations observed in t-AL occur and why the same 
translocations are seen repeatedly has puzzled clinicians and scientists for decades. We will focus on 
TOP2 poison associated t-AL, starting with the mechanism of action of TOP2 and TOP2 poisons and 
leading on to recent discoveries in topoisomerase biology that are relevant to the etiology of therapy-
related secondary leukemia. 
Table 1. Typical biological and clinical characteristics of t-AML cases associated with 
alkylating agents and TOP2 poisons. 
 TOP2 poison * associated 
(* such as etoposide, teniposide 
mitroxantrone, epirubicin) 
Alkylating agent 
$
 associated 
(
$
such as cyclophosphamide, 
melphalan, chlorambucil, and 
nitrosoureas)
Latency period 
Chromosome abnormalities 
Complex Karyotype 
Preceded by myelodisplastic 
syndrome
Age association 
Short, <2 years 
Recurrent translocations especially 
involving MLL at 11q23 and 
t(15;17)(PML-RARA), 
t(8,21)(AML-ETO) 
Rare 
Rare 
 
Younger 
2–8 years 
Deletions involving 
Chr 5 and 7 
 
Frequent 
Frequent 
 
Older 
2. TOP2 and TOP2 Poisons
DNA topoisomerase II, referred to as TOP2, is essential for cell survival and plays a role in 
replication, transcription, chromosome condensation and segregation [18–22]. It allows one double-
stranded DNA segment to pass through another, thus altering DNA topology. This is achieved by 
introducing a TOP2-bridged double-strand break into one DNA duplex, where each monomer of the 
dimeric enzyme remains covalently attached to the ends of the DSB via a 5’-phosphotyrosyl linkage 
(Figures 1 and 2). A second DNA segment is then passed through the enzyme-bridged DNA gate, and 
the break is re-ligated. The enzyme-bridged gate is normally a short lived intermediate, but TOP2 
poisons inhibit the religation step, resulting in the formation of an unusual type of DSB called a 
cleavage complex, in which the topoisomerase protein remains covalently coupled to the DNA 
(Figures 2 and 3). These breaks are cytotoxic, hence the utility of TOP2 in cancer therapy. 
Unfortunately, TOP2 poisons also have genotoxic side effects, including the formation of 
leukemogenic chromosome translocations. Humans and other vertebrates possess two type II 
topoisomerase paralogs, TOP2A and TOP2B, encoded by genes on chromosomes 17 and 3, 
respectively. TOP2B is the predominant form in quiescent and terminally differentiated cells, while 
TOP2A and TOP2B are both abundant in cycling cells [23,24].  
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Figure 2. TOP2 DNA cleavage. TOP2-catalyzed strand cleavage involves a reversible, 
covalent enzyme–DNA adduct formed through the TOP2 active site tyrosine residue. 
Topoisomerase poisons inhibit the reverse reaction (re-ligation) resulting in stabilization of 
the 5’ phosphotyrosyl-DNA complex (cleavage complex) which contains a TOP2-linked 
strand breaks. The TOP2 protein molecule is represented by the thick grey line. Only one 
TOP2 monomer and one strand of the DNA duplex are shown. 
Figure 3. TOP2 Poisons, downstream events. TOP2 poisons inhibit the religation step of 
the TOP2 reaction cycle, leading to accumulation of covalent TOP2-DNA cleavage 
complexes. These lesions are cytotoxic and lead to activation of the DNA damage response 
and potentially apoptosis. Alternatively these lesions are repaired, largely through the  
non-homologous end-joining pathway. Translocations observed in therapy-related 
leukemia are presumed to occur as a result of mis-repair, joining two heterologous ends. 
 
Clinically relevant TOP2 poisons fall into several chemical classes including epipodophyllotoxins, 
acridines, anthracylines, the anthacenedione mitoxantrone and the benzo[c]phenanthridine alkaloid 
NK314 (which is also reported to down-regulate non homologous end-joining) [25–27] (Table 2). 
Antibacterial quinolones such as ciprofloxacin act through poisoning of the bacterial type II DNA 
topoisomerase (DNA gyrase and topoisomerase IV) and recently voreloxin, a quinolone derivative that 
targets human TOP2 was described [28].  
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Table 2. TOP2 poisons, those that are or have been used clinically in cancer therapy are in bold. 
Chemical class Examples 
Epipodophyllotoxins Etoposide, Teniposode 
Anthracylines Doxorubicin, Epirubicin, Daunorubicin, Idarubicin, Aclarubicin
Anthacenedione Mitoxantrone  
Acridines m-AMSA (amsacrine), m-AMCA, AMCA, DACA 
Quinalones Voreloxin  
Benzo[c]phenanthridine alkaloid NK314  
In addition a number of naturally occurring compounds including selenite, curcumin, digitoxin, 
dietary flavonoids and the green-tea constituent EGCG inhibit TOP2 or induce TOP2-DNA complexes 
in cell culture studies [29–34] and it has been suggested that flavonoids and catechins derived from the 
maternal diet may contribute to in utero MLL translocations underlying neonatal leukemias through 
their activity as topoisomerase poisons II [29,30,35,36]. As discussed below, MLL translocations found 
in neonatal acute leukemia cases share molecular features with those in t-AML. 
The anthracyclines doxorubicin, daunorubicin and idarubicin and the anthracenedione, 
mitoxantrone differ from the epipodophyllotoxin TOP2 poisons (etoposide and teniposide) in that they 
are strong DNA intercalators. In addition to direct TOP2 poisoning and intercalation, ROS stimulated 
formaldehyde production, leads to the formation of anthracycline and mitoxantrone DNA adducts and 
crosslinks [37–41], which are presumably cytotoxic in their own right [42].  
3. TOP2 Poisons and Chromosome Translocations 
TOP2 is a well validated anti-cancer target and TOP2 poisons are widely used and effective 
therapeutic agents; but, as discussed above, they are associated with the occurrence of late 
complications, including therapy-related acute leukemia. It is hoped that a better understanding of the 
events leading to t-AL, in particular the mechanism by which t-AL recurrent translocations occur may 
help minimize these side effects. Detailed analysis of translocation breakpoints (the position in a 
derivative chromosome where the two heterologous chromosome segments are fused) and aspects of 
TOP2 biology have begun to shed light on the mechanisms by which these translocations occur.  
For some of the genes involved, including MLL, PML, RARA and AML1 (RUNX1) a relatively large 
number of translocation breakpoints from de novo and therapy related leukemia cases have been 
determined at the base pair level. What has emerged from this is that while t-AL related breakpoints 
fall within previously identified breakpoint clusters (BCRs), their distribution can be skewed compared 
to the distribution of de novo AML breakpoints. This is particularly noticeable for the MLL gene. 
Chromosomal breakpoints involved in MLL translocations in acute leukemia fall within an 8-Kb 
breakpoint cluster region (BCR), but breakpoints reported from t-AL and neonatal acute leukemia 
cases (<1 year) are concentrated in the most telomeric 1 Kb of this region, while breakpoints from de
novo cases cluster towards the centromeric end of this region (Figure 4) [43–45]. Similarly, for the 
PML gene, reported acute promyelocytic leukemia breakpoints fall into BCRs in introns three and six, 
but in leukemia cases associated with mitoxantrone treatment, there is a remarkably tight clustering of 
PML breakpoints within an 8 bp region of intron 6 [12,14]. This includes five cases of secondary 
leukemia following mitoxantrone treatment for multiple sclerosis [15] (see above). Returning to the 
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MLL gene, the similar distribution of t-AL and neonatal acute lymphoblastic leukemia MLL 
translocation breakpoints [44] is intriguing since MLL translocations are particularly common in infant 
acute leukemia [46] and it has been suggested that TOP2 poisons acting in utero may play a role in the 
etiology of infant leukemias [30,35,44,47]. The telomeric end of the MLL BCR also contains an area of 
DNase I hypersensitivity [48,49], cryptic promoter activity and binding by the transcription factor 
CTCF (see Figure 4) [50]. DNase I hypersensitivity results from increased chromatin accessibility and 
is characteristic of promoters and other transcriptional regulatory elements. Intriguingly, amongst 
reported t-AML and neonatal acute leukemia MLL translocations that have been described at the DNA 
sequence level there is a breaksite hotspot [51–53] that coincides with the peak of DNase I 
hypersensitivity and CTCF binding (Figure 4). It has been suggested that an unusual chromatin 
structure and/or cryptic promoter activity contributes to MLL translocation in t-AL and possibly 
neonatal acute leukemia [49,50,54]. Furthermore, DNase I hypersensitive sites are also associated with 
BCRs of other genes that are rearranged in t-AML translocations including AF9 and AF4 (common 
MLL translocation partners), and in the AML1/RUNX1 and ETO genes [48,55].  
Figure 4. MLL translocations. Top: Genomic organization of the MLL gene, exons are 
numbered. Horizontal rectangle, breakpoint cluster region (BCR). Bottom: Enlarged 
segment of the MLL locus encompassing the breakpoint region. SCI and SCII denote BCR 
subclusters in which de novo AML and t-AL/neonatal translocation breakpoints are 
concentrated respectively [45]. The asterisk denotes a “hotspot” where nine tightly 
clustered therapy related or neonatal breakpoints have been reported. The red-boxed region 
highlights a peak of CTCF binding and DNase I hypersensitivity observed in the publically 
available ENCODE data (http://genome.ucsc.edu/cgi-bin/hgGatewa [56–58]). 
 
Recently, it has emerged that TOP2B has a role in transcription, being involved in the 
transcriptional response to estrogen and other nuclear hormones in a manner that appears to involve 
transient DSB induction [59–63]. In addition, inhibitor studies suggest that etoposide-induced TOP2B 
cleavage complexes are proteolytically processed to reveal DSBs in a transcription-linked mechanism [64]. 
Furthermore, TOP2 is also thought to relieve positive supercoiling ahead of elongating RNA 
polymerase [65] and to be required for efficient transcription on chromatin templates [21], although 
this process may involve TOP2A rather than TOP2B. DNase I hypersensitivity and cryptic promoter 
activity, together with the connections between TOP2B and transcription led us to suggest that DSBs 
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introduced by TOP2B during transcription (and stabilized by a TOP2 poison) are the causative DSBs 
in chromosomal translocations in therapy related leukemia with anti-TOP2 drugs [66]. 
When considering mechanisms that facilitate recurrent chromosome translocations, the processes 
that generate DSBs are only part of the story. For translocation to occur the participating genes must 
also be in the same nuclear vicinity to allow interaction and aberrant end-joining. Processes that bring 
these genes together or facilitate their interaction would be expected to increase the risk of a 
translocation between them. Interphase genomes are non-randomly arranged in the nuclear space and 
the average distance between genes appears to affect translocation frequency [67]. While the processes 
that organize the chromosomes in the interphase nucleus are not well understood, a contributing factor 
and one that could be relevant to chromosome translocations especially in relation to t-AML is the now 
well accepted concept of transcription factories (see Figure 5).  
Figure 5. Clustering of transcription into transcription factories could facilitate chromosome 
translocation. Segments of two juxtaposed chromosomes are shown in red and blue. 
Transcription factories can contain active genes located on different chromosomes where 
these chromosomes come into contact and potentially intermingle [68]. Ongoing transcription 
in a shared transcription factory can maintain two heterologous chromosome segments in 
juxtaposition for the length of the transcription cycle (circled area, top part of the diagram) 
and it is hypothesized that this facilitates translocation when DNA breaks are induced. In the 
case of t-AML related translocations breaks are introduced by the action of TOP2 poisons.
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Transcription occurs at dynamic structures called factories or hubs [69] consisting of multiple active 
RNA polymerase complexes each engaged with a transcription unit (gene) [70]. The dynamic 
association of genes with these focal sites of transcription results in looping and loops are presumed to 
form as transcription initiates, remain associated while transcription proceeds and then redistribute as 
transcription terminates (Figure 5). Since interphase chromosomes occupy distinct territories in the 
nucleus [68], transcription units derived from proximal regions of the same chromosome are likely to 
share transcription factories with the greatest frequency. However, high resolution FISH has 
demonstrated significant intermingling of chromatin between adjacent chromosome territories [68].  
As a result genes residing on different chromosomes can simultaneously associate with common 
transcription factories, as has been demonstrated using RNA FISH to visualize sites of ongoing 
transcription [71,72]. In the context of hematological malignancies, the Igh and Myc genes (which are 
involved in translocations in B-cell lymphoma such that the proto-oncogene Myc is driven by the 
active Igh promoter) frequently share sites of transcription in stimulated mouse B cells [73]. Thus, 
sharing of transcription factories combined with transcription-associated TOP2-poison mediated DSBs 
could provide both the DSBs and the juxtaposition required for chromosome translocation (see Figure 5) 
in therapy related leukemias. 
A key question concerning the etiology of the specific translocations observed in therapy related acute 
leukemia is why the MLL breakpoints occur in such a restricted genomic region in t-AL and neonatal 
acute leukemia compared to de novo AML (see Figure 4). This region is sensitive to etoposide-induced 
cleavage in cell line studies [49,50,74]; however, two distinct mechanisms have been implicated as 
sources of this sensitivity. The first is direct TOP2-mediated cleavage (as illustrated in Figure 3) and 
the second is related to early CAD-mediated apoptotic fragmentation [74–76]. The former model 
appears the simplest, and base-pair resolution mapping revealed etoposide-induced TOP2-mediated 
cleavage and DNA breaks in the SCII region of the MLL BCR, but notably it did not demonstrate 
preferential TOP2 mediated cleavage at the translocation hotspot referred to above [50,74] (Figures 4 
and 6). Higher order chromatin fragmentation occurring during TOP2 poison induced apoptosis was 
proposed as an alternative mechanism for initiation of t-AL–associated chromosomal translocations in 
cells that ultimately evade apoptosis and divide [74–76]. Base-pair resolution mapping revealed a 
major apoptotic cleavage region in MLL exon 12, however this is downstream of the BCR and more 
than 200 bp from the hotspot of MLL breaksites [74] (Figures 4 and 6). Thus, the clustering of t-AML 
breakpoints cannot be explained simply by direct TOP2-mediated or apoptotic higher order cleavage 
patterns alone, but might result from interactions between these processes in conjunction with end-
resection and other events associated with aberrant repair, or as discussed above, with transcription. 
Interestingly, the hotspot of t-AL break sites described above is centered on an ATTA motif that is 
also found in the etoposide-stabilized TOP2B-associated cleavage site reported in the pS2/TFF1 
promoter (Figure 6) [59]. Although there is no strong consensus for optimum TOP2 cleavage  
sites [77], there is an apparent preference for A/T residues in the +1 to +4 positions which correspond 
to the 5’-overhang generated by TOP2 cleavage (Figure 6). TOP2 cleavage events at sites in two 
translocation partner genes could generate homologous 4 bp single-stranded overhangs (after cleavage 
complex processing, see below) that anneal to form junction sequences that are repaired by non-
homologous end joining in an aberrant repair reaction (Figure 5). This type of reciprocal cleavage 
followed by aberrant joining between TAATTA sequences may account for a minority of MLL-AF9 
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translocation events [52], but analysis of translocation junction sequences suggests that aberant joining 
typically involves resection to reveal microhomologies in the partner chromosomes [53,78]. It should 
be noted that the precise biochemical steps in the normal repair process through which TOP2 
complexes are processed to yield DNA ends that can be ligated are not fully understood. For TOP2B, 
this process can include transcription dependent proteasomal degradation of covalently coupled 
TOP2B [64], which may be followed by additional “end polishing” steps. This type of processing 
would be compatible with direct aberrant joining of the resulting staggered ends or resection to reveal 
microhomologies prior to joining.
Figure 6. MLL translocation hotspot. MLL breakpoint sequences (der 11) from t-AL cases 
that form a “hotspot” near the telomeric end of the MLL BCR. The ATTA sequence is 
aligned with the same 4bp sequence identified in the etoposide-induced cleavage site 
described in the pS2 promoter [59].  
4. Conclusions and Possible Approaches to Reducing T-AML Associated Chromosome 
Translocations
TOP2 poisons are useful and effective anti-cancer drugs, but they are associated with therapy-related 
secondary leukemia, often bearing 11q23 translocations involving the MLL gene. The distribution of 
MLL chromosomal breakpoints in t-AL cases differs from that observed for de novo AML with 
clustering at the 3’-region of intron 11 associated with a region of DNase I hypersensitivity and CTCF 
binding (Figures 4 and 6). Neither direct TOP2-mediated cleavage nor early apoptotic processes alone 
appear to explain the distribution of MLL break sites. Instead, interaction between these processes 
and/or with events downstream of initial DNA cleavage and other factors such as chromatin 
accessibility and ongoing transcription may influence t-AML translocation [48–50]. For drugs such as 
etoposide, TOP2A appears to be the most important of the two TOP2 isoforms with regard to induced 
cytotoxicity and therefore anti-cancer activity [26]. Despite this, we and others have found that 
etoposide-induced genotoxicity is largely dependent on TOP2B [30,66,79]. Recent data has revealed 
an important and unexpected role for TOP2B in transcription [59–61] and transcription dependent 
processing of TOP2B cleavage complexes to DSBs. The possibility that this is connected to the 
apparent genotoxic potential of TOP2B in the presence of TOP2 poisons provides an intriguing area 
for further study which will provide a better understanding of the events that trigger chromosome 
translocations in t-AL and could lead to strategies to minimize the occurrence of leukemia after 
treatment for a primary malignancy. One such strategy is specific TOP2 poison targeting of TOP2A, 
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since genotoxic effects appear to be mostly mediated by TOP2B [66]. In fact, the TOP2 poisons shown 
in Table 1 are not identical in their relative activities against TOP2A and TOP2B and TOP2 poisons 
have been described that preferentially target one or the other isoform [26,80,81]. Similarly, if 
transcription-dependent, TOP2B mediated DSBs trigger t-AL translocations as suggested above, then 
harmful genotoxic effects may be minimized by employing anti-cancer regimens in which a 
transcriptional inhibitor precedes administration of a TOP2 poison. Notably transcription inhibitors are 
currently under investigation as potential anti-cancer agents in their own right [82]. As understanding 
of the molecular events leading to TOP2 poison associated t-AL improves we are optimistic that 
strategies can be identified that will minimize the occurrence of secondary effects such as therapy 
related leukemia following use of this extremely useful class of anti-cancer agent.
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